Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,043 shares of the life sciences company’s stock after selling 320 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Illumina were worth $967,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of ILMN. Trivant Custom Portfolio Group LLC lifted its stake in Illumina by 166.7% during the first quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after buying an additional 125 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new position in shares of Illumina in the 4th quarter valued at about $37,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 86.8% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares during the period. Gradient Investments LLC increased its holdings in shares of Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the period. Finally, MeadowBrook Investment Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $42,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN traded down $1.59 during midday trading on Friday, reaching $114.20. The company’s stock had a trading volume of 728,278 shares, compared to its average volume of 2,155,876. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $195.64. The company has a market capitalization of $18.19 billion, a P/E ratio of -14.17 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The business’s fifty day simple moving average is $109.43 and its 200-day simple moving average is $125.00.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period last year, the company posted $0.08 earnings per share. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. As a group, equities research analysts expect that Illumina, Inc. will post 0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. Barclays upped their target price on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a report on Wednesday, April 10th. Evercore ISI dropped their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a report on Tuesday, June 11th. Royal Bank of Canada dropped their target price on Illumina from $249.00 to $242.00 and set an “outperform” rating on the stock in a report on Monday, July 1st. Scotiabank dropped their price objective on Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a report on Monday, May 6th. Finally, Robert W. Baird increased their price objective on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $158.57.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.